Conference abstractPublished 21 Oct 2013
USA and EU regulatory submissions for veterinary medicines
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The USA and the EU are the 2 major animal health markets in the world. A combined USA/EU drug development approach allows pharmaceutical companies to co-ordinate resources, shorten development times, promote financial efficiency and ultimately expand revenue. However, a combined approach faces many challenges, as both the USA and EU have significantly different regulatory frameworks, timeframes and requirements. In such a highly regulated industry, knowledge of both USA and EU regulatory requirements, procedure, policy and standards is crucial in order to conduct joint USA/EU programs of development, prepare dossiers for submission and obtain marketing authorizations in both territories. This presentation will describe the similarities and differences between the USA and EU requirements for obtaining a marketing authorization for a veterinary medicinal Product.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Karolina Bate”
